Stock Research: Dermapharm

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Dermapharm

GER:DMP DE000A2GS5D8
42
  • Value
    84
  • Growth
    41
  • Safety
    Safety
    49
  • Combined
    58
  • Sentiment
    19
  • 360° View
    360° View
    42
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 42 (better than 42% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dermapharm are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Dermapharm. Only the consolidated Value Rank has an attractive rank of 84, which means that the share price of Dermapharm is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 84% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 41, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 49, meaning the company has a riskier financing structure than 51% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 81% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 19. ...read more

more
Index
CDAX
SDAX
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-Jul-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 n/a n/a n/a
Growth
41 n/a n/a n/a
Safety
Safety
49 n/a n/a n/a
Sentiment
19 n/a n/a n/a
360° View
360° View
42 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
31 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
34 n/a n/a n/a
Sentiment
19 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 n/a n/a n/a
Growth
41 n/a n/a n/a
Safety Safety
49 n/a n/a n/a
Combined
58 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
83 n/a n/a n/a
Price vs. Earnings (P/E)
52 n/a n/a n/a
Price vs. Book (P/B)
58 n/a n/a n/a
Dividend Yield
77 n/a n/a n/a
Value
84 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
39 n/a n/a n/a
Profit Growth
49 n/a n/a n/a
Capital Growth
50 n/a n/a n/a
Stock Returns
63 n/a n/a n/a
Growth
41 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
9 n/a n/a n/a
Refinancing
88 n/a n/a n/a
Liquidity
46 n/a n/a n/a
Safety Safety
49 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Dermapharm and broaden your portfolio horizons.

Lufthansa

GER:LHA
Country: Germany
Industry: Airlines
Size: X-Large
Full Stock Analysis

Volkswagen VW

GER:VOW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Freenet

GER:FNTN
Country: Germany
Industry: Wireless Telecommunication
Size: Large
Full Stock Analysis

Drägerwerk

GER:DRW8
Country: Germany
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: